Role of Neurotrophins in the Development of the Mammalian Nervous System

点击翻译按钮获取中文摘要

TrkB and TrkC encode a number of isoforms, including those that lack the catalytic tyrosine kinase domain. Little is known about the function of these kinase deficient isoforms in Trk signaling. In vitro studies, and our own in vivo studies, have shown that truncated Trk receptors can inhibit the function of kinase-active receptor isoforms in a dominant-negative manner or by ligand sequestration. The physiological relevance of this activity is, however, still unclear. The high degree of sequence conservation of the intracellular domains of truncated receptors suggests the potential for specific interactions with cytoplasmic proteins and signaling capabilities. Indeed, it has been reported recently that BDNF induces the production of calcium waves in astroglia through the truncated TrkB T1 receptor. However, the molecular mechanism(s) linking the TrkB T1 receptor to calcium mobilization and its physiological role is still unknown. Interestingly, TrkB T1 is 50% overexpressed in the brain of the trisomy 16 (Ts16) mouse model of Down syndrome and Ts16 hippocampal neurons die prematurely in culture. Neurodegeneration is commonly associated with Down syndrome in humans and TrkB T1 is also overexpressed in Alzheimer's patients. To further investigate the role of TrkB T1 in neuronal survival, we generated a mouse lacking specifically the TrkBT1 kinase-deficient receptor isoform. This mutation caused no gross phenotype and could be used to correct the levels of TrkB T1 in Ts16 mice in vivo. Importantly, hippocampal neurons from TrkB T1 -/+; Ts16 mice escaped the premature cell death of Ts16 neurons in vitro (Dorsey et al. 2006). This is a very exciting result because it contrasts with earlier hypotheses that neurodegeneration occurs due to insufficient supply of neurotrophic factors. Rather, our studies suggest that modulation of cell death and survival can occur at the level of the Trk receptor. We are now investigating the molecular mechanisms leading to the dysregulation of TrkB.T1 levels and underlying the detrimental effect of elevated TrkB T1 expression. Specifically, we are addressing both the effects of TrkBT1 on the activity of the full-length TrkB receptor and on the intracellular regulation of Ca++ levels. In this respect we have found that TrkB.T1 deficient mice develop normally but show increased anxiety in association with morphological abnormalities in the length and complexity of neurites of neurons in the basolateral amygdala. In vivo reduction of TrkB signaling by removal of one BDNF allele could be partially rescued by TrkB.T1 deletion, which was revealed by an amelioration of the enhanced aggression and weight gain associated to BDNF haploinsufficiency. Thus, our results provide evidence that at the physiological level, TrkB.T1 receptors are important regulators of TrkB.FL signaling in vivo. In addition, we have recently found that upregulation of Rbfox1, an RNA binding protein associated with intellectual disability, epilepsy and autism, increases selectively hippocampal TrkB.T1 isoform expression. Physiologically, increased Rbfox1 impairs BDNF-dependent LTP which can be rescued by genetically restoring TrkB.T1 levels. RNA-seq analysis of hippocampi with upregulation of Rbfox1 in conjunction with the specific increase of TrkB.T1 isoform expression also shows that the genes affected by Rbfox1 gain of function are surprisingly different from those influenced by Rbfox1 deletion. These findings not only identify TrkB as a major target of Rbfox1 pathophysiology but also suggest that gain or loss of function of Rbfox1 regulate different genetic landscapes. Another important area of research of my laboratory is focused on the in vivo dissection of the function of the domains of Trk receptor complex structure in both the extracellular and intracellular regions to identify mechanisms and/or proteins that regulate receptor activation and function in specific cell types and neuronal circuitries. So far, we have shown that a three amino-acid intracellular domain in the juxtamembrane region of TrkA (KFG) regulates the receptor ubiquitination and function. With this mouse model we identified a new function of TrkA signaling in the basal forebrain cholinergic region in the regulation of fear response and fear expression. Our findings also have profound implications for patients undergoing cancer therapy. The finding that TrkA expressing Basal Forebrain Cholinergic neurons regulate fear circuitries and may influence development of PTSD raises the question of whether treatment of cancer patients with pan-Trk inhibitors put them at higher risk of developing PTSD. Currently, we have begun the characterization of the in vivo function of the leucine rich repeat (LRR) domain in the extracellular region of the TrkB receptors in a recently generated mouse model with such mutation. Since LRRs are found in many neural cell-adhesion molecules and are implicated in axon guidance, target selection, synapse formation and in synaptogenic adhesions we expect that this work will help us identify the molecular mechanism underlying TrkB function in the regulation of complex behaviors.